ATC Abstracts

American Transplant Congress abstracts

  • Home
  • Meetings Archive
    • 2022 American Transplant Congress
    • 2021 American Transplant Congress
    • 2020 American Transplant Congress
    • 2019 American Transplant Congress
    • 2018 American Transplant Congress
    • 2017 American Transplant Congress
    • 2016 American Transplant Congress
    • 2015 American Transplant Congress
    • 2013 American Transplant Congress
  • Keyword Index
  • Resources
    • 2021 Resources
    • 2016 Resources
      • 2016 Welcome Letter
      • ATC 2016 Program Planning Committees
      • ASTS Council 2015-2016
      • AST Board of Directors 2015-2016
    • 2015 Resources
      • 2015 Welcome Letter
      • ATC 2015 Program Planning Committees
      • ASTS Council 2014-2015
      • AST Board of Directors 2014-2015
      • 2015 Conference Schedule
  • Search

12-Months Evolution of Anti-HLA Antibodies Donor Specific Antibodies after Rescue Switch from CNi-Based Immunosuppressive Regimen to Belatacept in Kidney Allograft Recipients

M. Matignon,1 C. Dudreuilh,1 P. Rémy,1 J-.L. Taupin,2 P. Grimbert.1

1Nephrology Transplantation, APHP Henri Mondor, Creteil, France
2Histocompatibility, APHP Saint Louis, Paris, France.

Meeting: 2018 American Transplant Congress

Abstract number: C73

Keywords: Immunosuppression, Rejection, Safety

Session Information

Session Name: Poster Session C: Kidney Immunosuppression: Novel Regimens and Drug Minimization

Session Type: Poster Session

Date: Monday, June 4, 2018

Session Time: 6:00pm-7:00pm

 Presentation Time: 6:00pm-7:00pm

Location: Hall 4EF

Introduction

After kidney transplantation, long-term immunosuppression with calcineurin inhibitors (CNIs) or mTOR inhibitors (mTORi) leads to adverse effects, such as nephrotoxicity and proteinuria. Currently, available data support use of belatacept as rescue therapy in patients with suboptimal allograft function and/or proteinuria. Evolution of anti-HLA donor specific antibodies (DSA) after switch is not known.

Patients and methods

We conducted a retrospective study including all kidney allograft recipients (>18 years, EBV +), followed from 01/2012 and 12/2015, after conversion from CNI-based immunosuppressive regimen to belatacept at any time after transplant with 12 months follow-up after switch. We compared DSA before switch and 12-months after. DSAs were assessed with Luminex single-antigen bead assays.

Results

A total of 47 patients were included from 01/2012 and 12/2015. Switch median delay after transplant was 14 (3.25-52.75) months with N=12 (25%) early switches (<3 months).

DSA were detectable in 16 (34%) patients before the switch and 18 (38%) patients after 12-months. All DSAs characteristics were similar between both time points.

Anti-HLA donor specific antibodies At the time of switch 12-months follow-up P-value
Patients' number, N (%) 47 (100) 47 (100)
Positive, N (%) 16 (34) 18 (38) 0.83
Class I, N (%) 9 (56) 6 (33) 0.72
Class I, Number, median (IQR) 1 (1-1.5) 1.5 (1-2) 1.00
Class I, MFI max, median (IQR) 1130 (696-2188) 1279 (945-2569) 0.84
Class I, MFI sum, median (IQR) 1637 (664-2388) 1983 (1460-2569) 1.00
Class II, N (%) 11 (69) 15 (83) 0.43
Class II, Number, median (IQR) 1 (1-2) 1 (1-2) 1.00
Class II, MFI max, median (IQR) 1709 (1157-2911) 1470 (704-3963) 0.57
Class II, MFI sum, median (IQR) 2284 (1178-3495) 1474 (1046-5941) 0.57

Conclusion

Belatacept as rescue therapy is safe regarding immunologic risk with a comparable immunization at the time of the switch compared to 12-months follow-up whatever the characteristics of DSA is considered.

CITATION INFORMATION: Matignon M., Dudreuilh C., Rémy P., Taupin J-.L., Grimbert P. 12-Months Evolution of Anti-HLA Antibodies Donor Specific Antibodies after Rescue Switch from CNi-Based Immunosuppressive Regimen to Belatacept in Kidney Allograft Recipients Am J Transplant. 2017;17 (suppl 3).

  • Tweet
  • Click to email a link to a friend (Opens in new window) Email
  • Click to print (Opens in new window) Print

To cite this abstract in AMA style:

Matignon M, Dudreuilh C, Rémy P, Taupin J-L, Grimbert P. 12-Months Evolution of Anti-HLA Antibodies Donor Specific Antibodies after Rescue Switch from CNi-Based Immunosuppressive Regimen to Belatacept in Kidney Allograft Recipients [abstract]. https://atcmeetingabstracts.com/abstract/12-months-evolution-of-anti-hla-antibodies-donor-specific-antibodies-after-rescue-switch-from-cni-based-immunosuppressive-regimen-to-belatacept-in-kidney-allograft-recipients/. Accessed May 16, 2025.

« Back to 2018 American Transplant Congress

Visit Our Partner Sites

American Transplant Congress (ATC)

Visit the official site for the American Transplant Congress »

American Journal of Transplantation

The official publication for the American Society of Transplantation (AST) and the American Society of Transplant Surgeons (ASTS) »

American Society of Transplantation (AST)

An organization of more than 3000 professionals dedicated to advancing the field of transplantation. »

American Society of Transplant Surgeons (ASTS)

The society represents approximately 1,800 professionals dedicated to excellence in transplantation surgery. »

Copyright © 2013-2025 by American Society of Transplantation and the American Society of Transplant Surgeons. All rights reserved.

Privacy Policy | Terms of Use | Cookie Preferences